MSFT   182.92 (-0.32%)
FB   235.67 (+0.32%)
AMZN   2,432.14 (-0.19%)
CGC   20.29 (+4.48%)
BABA   203.69 (+2.00%)
GE   6.83 (+6.55%)
AMD   54.51 (-1.20%)
T   30.94 (+3.51%)
ACB   15.64 (-2.31%)
F   5.86 (+3.72%)
GILD   73.79 (+0.61%)
BAC   24.17 (+6.62%)
BA   143.69 (+4.48%)
MSFT   182.92 (-0.32%)
FB   235.67 (+0.32%)
AMZN   2,432.14 (-0.19%)
CGC   20.29 (+4.48%)
BABA   203.69 (+2.00%)
GE   6.83 (+6.55%)
AMD   54.51 (-1.20%)
T   30.94 (+3.51%)
ACB   15.64 (-2.31%)
F   5.86 (+3.72%)
GILD   73.79 (+0.61%)
BAC   24.17 (+6.62%)
BA   143.69 (+4.48%)
MSFT   182.92 (-0.32%)
FB   235.67 (+0.32%)
AMZN   2,432.14 (-0.19%)
CGC   20.29 (+4.48%)
BABA   203.69 (+2.00%)
GE   6.83 (+6.55%)
AMD   54.51 (-1.20%)
T   30.94 (+3.51%)
ACB   15.64 (-2.31%)
F   5.86 (+3.72%)
GILD   73.79 (+0.61%)
BAC   24.17 (+6.62%)
BA   143.69 (+4.48%)
MSFT   182.92 (-0.32%)
FB   235.67 (+0.32%)
AMZN   2,432.14 (-0.19%)
CGC   20.29 (+4.48%)
BABA   203.69 (+2.00%)
GE   6.83 (+6.55%)
AMD   54.51 (-1.20%)
T   30.94 (+3.51%)
ACB   15.64 (-2.31%)
F   5.86 (+3.72%)
GILD   73.79 (+0.61%)
BAC   24.17 (+6.62%)
BA   143.69 (+4.48%)
Log in

TSE:FRXFennec Pharmaceuticals Stock Price, Forecast & News

C$10.45
-0.05 (-0.48 %)
(As of 05/26/2020 12:05 PM ET)
Add
Compare
Today's Range
C$10.45
Now: C$10.45
C$10.45
50-Day Range
C$7.84
MA: C$9.60
C$10.50
52-Week Range
C$4.35
Now: C$10.45
C$11.04
Volume412 shs
Average Volume1,410 shs
Market CapitalizationC$264.97 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-919-6364530

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.71 per share
Book ValueC$0.60 per share

Profitability

Miscellaneous

Employees3
Market CapC$264.97 million
Next Earnings Date8/14/2020 (Estimated)
OptionableNot Optionable

Receive FRX News and Ratings via Email

Sign-up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter.

Fennec Pharmaceuticals (TSE:FRX) Frequently Asked Questions

How has Fennec Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Fennec Pharmaceuticals' stock was trading at C$9.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FRX stock has increased by 15.9% and is now trading at C$10.45. View which stocks have been most impacted by Coronavirus.

When is Fennec Pharmaceuticals' next earnings date?

Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Fennec Pharmaceuticals.

Has Fennec Pharmaceuticals been receiving favorable news coverage?

Headlines about FRX stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Fennec Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutFennec Pharmaceuticals.

Who are some of Fennec Pharmaceuticals' key competitors?

What other stocks do shareholders of Fennec Pharmaceuticals own?

Who are Fennec Pharmaceuticals' key executives?

Fennec Pharmaceuticals' management team includes the following people:
  • Mr. Rostislav Raykov, CEO & Director (Age 43)
  • Mr. Robert C. Andrade, Chief Financial Officer (Age 44)
  • Mr. Mark Gowland, Controller
  • Mr. Lei Fang, Pres of Pharstat Inc
  • Ms. Anne McKay, Regulatory Consultant (Age 65)

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "FRX."

How do I buy shares of Fennec Pharmaceuticals?

Shares of FRX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Fennec Pharmaceuticals' stock price today?

One share of FRX stock can currently be purchased for approximately C$10.45.

How big of a company is Fennec Pharmaceuticals?

Fennec Pharmaceuticals has a market capitalization of C$264.97 million. Fennec Pharmaceuticals employs 3 workers across the globe.

What is Fennec Pharmaceuticals' official website?

The official website for Fennec Pharmaceuticals is fennecpharma.com.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is 68 Tw Alexander Dr PO Box 13628, DURHAM, NC 27709-3628, United States. The biopharmaceutical company can be reached via phone at +1-919-6364530.

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.